Telitacicept  (Synonyms: RC18)

Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease^[1]. The component ratio of this product is Active ingredient : Excipients = 1: 0.5-1: 0.8.

(BLyS)/APRIL^[1]

Telitacicept (15 and 7.5mpk, i.p.) improves mouse experimental autoimmune encephalomyelitis (EAE) clinical symptoms in MOG_35-55 induced EAE model mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

75.36 kDa

2136630-26-5

Solid

White to off-white

[Telitacicept]

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  [TNFRSF13B (tumor necrosis factor receptor (TNFR)superfamily member 13B, TACI, transmembrane activator and CAML Interactor)]2-IGHG1 Fc (Fragment constant)

• 
  Immobilized BAFF/TNFSF13B Protein, Human (CHO, HY-P7003) can bind Telitacicept. The EC₅₀ for this effect is 14.06 ng/mL.

• [1]. Yao X, et, al. Pharmacokinetics analysis based on target-mediated drug distribution for RC18, a novel BLyS/APRIL fusion protein to treat systemic lupus erythematosus and rheumatoid arthritis. Eur J Pharm Sci. 2021 Apr 1;159:105704.   [Content Brief]

  [2]. Yuxi Yan, et al. Experimental Autoimmune Encephalomyelitis Animal Models Induced by Different Myelin Antigens Exhibit Differential Pharmacologic Responses to Anti-Inflammatory Drugs. Journal of Immunological Sciences. March 31, 2022.